{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:51:55Z","timestamp":1791579115092,"version":"4.3.4"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian Government\u2019s Cooperative Research Centre Scheme","award":["2.3.4"],"award-info":[{"award-number":["2.3.4"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biotechnology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jbiotec.2016.10.022","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T08:15:48Z","timestamp":1477556148000},"page":"48-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation"],"prefix":"10.1016","volume":"240","author":[{"given":"Ali","family":"Razaghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Heimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbiotec.2016.10.022_bib0005","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2008.01.005","volume":"109","author":"Alberts","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/hyb.1987.6.509","article-title":"Production of monoclonal antibodies against recombinant human interferon-gamma: screening of hybridomas without purified antigen","volume":"6","author":"Alfa","year":"1987","journal-title":"Hybridoma"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0015","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","article-title":"Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo","volume":"80","author":"Ank","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0020","doi-asserted-by":"crossref","first-page":"14435","DOI":"10.1016\/S0021-9258(17)38587-3","article-title":"Preparation and characterization of recombinant DNA-derived human interferon-gamma","volume":"260","author":"Arakawa","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0025","first-page":"87","article-title":"Cloning and expression of human gamma-interferon on cDNA in E coli","volume":"1","author":"Arbabi","year":"2003","journal-title":"Iran. J. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0030","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/j.1600-6143.2010.03094.x","article-title":"Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients","volume":"10","author":"Armstrong-James","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0168-1656(96)01636-7","article-title":"Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies","volume":"52","author":"Arora","year":"1996","journal-title":"J. Biotechnol."},{"issue":"Suppl. 1","key":"10.1016\/j.jbiotec.2016.10.022_bib0040","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/cid\/cis361","article-title":"Global burden of hepatitis C: considerations for healthcare providers in the United States","volume":"55","author":"Averhoff","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.procbio.2006.07.009","article-title":"Over-production of human interferon-\u03b3 by HCDC of recombinant Escherichia coli","volume":"42","author":"Babaeipour","year":"2007","journal-title":"Process Biochem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0050","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1007\/s12010-009-8718-5","article-title":"Enhancement of human \u03b3-interferon production in recombinant E. coli using batch cultivation","volume":"160","author":"Babaeipour","year":"2010","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0055","first-page":"563","article-title":"Maximizing production of human interferon-gamma in HCDC of recombinant E. coli","volume":"12","author":"Babaeipour","year":"2013","journal-title":"Iran. J. Pharm. Res"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev.immunol.15.1.563","article-title":"The IFN gamma receptor: a paradigm for cytokine receptor signaling","volume":"15","author":"Bach","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10528-010-9403-7","article-title":"Expression of biologically active human interferon gamma in the milk of transgenic mice under the control of the murine whey acidic protein gene promoter","volume":"49","author":"Bagis","year":"2011","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12257-007-0126-5","article-title":"Optimization of human interferon gamma production in Escherichia coli by response surface methodology","volume":"13","author":"Balderas Hern\u00e1ndez","year":"2008","journal-title":"Biotechnol. Bioproc. E"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.it.2010.12.003","article-title":"Inflammatory signals regulate hematopoietic stem cells","volume":"32","author":"Baldridge","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0080","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1461-5347(00)00264-9","article-title":"Therapeutic potential for orally administered type 1 interferons","volume":"3","author":"Beilharz","year":"2000","journal-title":"Pharm. Sci. Technol. Today"},{"issue":"Pt 4","key":"10.1016\/j.jbiotec.2016.10.022_bib0085","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/0022-1317-66-4-887","article-title":"Catabolic sites of human interferon-gamma","volume":"66","author":"Bocci","year":"1985","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0090","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0095","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/14712598.6.10.1051","article-title":"Interferon-\u03b31b for the treatment of idiopathic pulmonary fibrosis","volume":"6","author":"Bouros","year":"2006","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1574-6976.2000.tb00532.x","article-title":"Heterologous protein expression in the methylotrophic yeast Pichia pastoris","volume":"24","author":"Cereghino","year":"2000","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11248-004-2376-8","article-title":"Expression of bioactive human interferon-gamma in transgenic rice cell suspension cultures","volume":"13","author":"Chen","year":"2004","journal-title":"Transgenic Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0110","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1271\/bbb.110107","article-title":"Expression of recombinant human interferon-gamma with antiviral activity in the bi-cistronic baculovirus-insect\/larval system","volume":"75","author":"Chen","year":"2011","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.0960-7420.2001.00281.x","article-title":"Two new polymorphisms in the human interferon gamma (IFN-gamma) promoter","volume":"29","author":"Chevillard","year":"2002","journal-title":"Eur. J. Immunogenet."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0120","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ces.2005.03.031","article-title":"Production of recombinant proteins by high cell density culture of Escherichia coli","volume":"61","author":"Choi","year":"2006","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0125","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jbiotec.2013.07.011","article-title":"Enhanced expression of codon optimized interferon gamma in CHO cells","volume":"167","author":"Chung","year":"2013","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2144\/000112943","article-title":"Interferon gamma: activity and ELISA detection comparisons","volume":"45","author":"Crisafulli","year":"2008","journal-title":"Biotechniques"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0135","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/hep.20467","article-title":"Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study","volume":"40","author":"Dalgard","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0140","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s11274-010-0648-4","article-title":"Cloning and expression of human IFN-\u03b3 in Leishmania tarentolae","volume":"27","author":"Davoudi","year":"2011","journal-title":"World J. Microbiol. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0145","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/nar\/11.6.1819","article-title":"Expression of the human interferon-gamma cDNA in yeast","volume":"11","author":"Derynck","year":"1983","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.49.2.251","article-title":"Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis","volume":"49","author":"Detjen","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0155","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0160","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0165","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1126\/science.1902591","article-title":"Three-dimensional structure of recombinant human interferon-gamma","volume":"252","author":"Ealick","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0170","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.5504\/bbeq.2012.0004","article-title":"Cloning, transformation and expression of human gamma interferon gene in tomato (Lycopersicon Esculentum Mill.)","volume":"26","author":"Ebrahimi","year":"2012","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0175","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","article-title":"Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial","volume":"14","author":"Eggermont","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0180","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1146\/annurev.iy.11.040193.003035","article-title":"The molecular cell biology of interferon-gamma and its receptor","volume":"11","author":"Farrar","year":"1993","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/biof.6","article-title":"Interferons and viral infections","volume":"35","author":"Fensterl","year":"2009","journal-title":"Biofactors"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0190","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1471-4906(01)02005-1","article-title":"IFN-gamma production by antigen-presenting cells: mechanisms emerge","volume":"22","author":"Frucht","year":"2001","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jbiotec.2004.06.006","article-title":"Refolding and purification of interferon-gamma in industry by hydrophobic interaction chromatography","volume":"113","author":"Geng","year":"2004","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0200","first-page":"5550","article-title":"The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence","volume":"9","author":"Giannopoulos","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0205","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199804303381804","article-title":"Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma","volume":"338","author":"Gleave","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0210","article-title":"Huge growth seen in hepatitis C market","volume":"39","author":"Gohil","year":"2014","journal-title":"P T"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0215","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/295503a0","article-title":"Expression of human immune interferon cDNA in E. coli and monkey cells","volume":"295","author":"Gray","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF02932581","article-title":"Refolding and purification of recombinant human interferon-\u03b3 expressed as inclusion bodies in Escherichia coli using size exclusion chromatography","volume":"10","author":"Guan","year":"2005","journal-title":"Biotechnol. Bioproc. E"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0225","doi-asserted-by":"crossref","first-page":"14746","DOI":"10.1039\/c2jm31972a","article-title":"The apoptosis of OVCAR-3 induced by TNF-\u03b1 plus IFN-\u03b3 co-immobilized polylactic acid copolymers","volume":"22","author":"Guan","year":"2012","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0230","first-page":"1163","article-title":"A rapid single-step purification method for human interferon-gamma from isolated Escherichia coli inclusion bodies","volume":"37","author":"Haelewyn","year":"1995","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0235","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0022-5347(17)38538-5","article-title":"The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines","volume":"145","author":"Hawkyard","year":"1991","journal-title":"J. Urol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0240","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/11.3.687","article-title":"Constitutive, long-term production of human interferons by hamster cells contalning multiple copies of a cloned interferon gene","volume":"11","author":"Haynes","year":"1983","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0245","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/jir.1987.7.145","article-title":"Differential purification by immunoaffinity chromatography of two carboxy-terminal portion-deleted derivatives of recombinant human interferon-gamma from Escherichia coli","volume":"7","author":"Honda","year":"1987","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0250","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/jir.1998.18.287","article-title":"The glycosylation heterogeneity of recombinant human IFN-gamma","volume":"18","author":"Hooker","year":"1998","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0255","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0260","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bej.2013.02.015","article-title":"Refolding of recombinant human interferon gamma inclusion bodies in vitro assisted by colloidal thermo-sensitive poly(N-isopropylacrylamide) brushes grafted onto the surface of uniform polystyrene cores","volume":"74","author":"Huang","year":"2013","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0265","first-page":"592","article-title":"N-glycosylation of recombinant human interferon-gamma produced in different animal expression systems","volume":"13","author":"James","year":"1995","journal-title":"Biotechnology (N.Y.)"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0270","first-page":"62","article-title":"Modeling bioprocess cost: economic benefits of expression technology based on Pseudomonas fluorescens","volume":"8","author":"Janice","year":"2010","journal-title":"Bioprocess Int."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0275","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/bit.20763","article-title":"On-column refolding of recombinant human interferon-gamma inclusion bodies by expanded bed adsorption chromatography","volume":"93","author":"Jin","year":"2006","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0280","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","article-title":"Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities","volume":"6","author":"Jonasch","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0285","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/S0021-9258(20)82020-1","article-title":"Effects of glycosidase treatment on the physicochemical properties and biological activity of human interferon-gamma","volume":"258","author":"Kelker","year":"1983","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0290","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1023\/B:BILE.0000004390.98648.25","article-title":"Over-expression of recombinant human interferon-gamma in high cell density fermentation of Escherichia coli","volume":"25","author":"Khalilzadeh","year":"2003","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0295","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10295-004-0117-x","article-title":"Process development for production of recombinant human interferon-gamma expressed in Escherichia coli","volume":"31","author":"Khalilzadeh","year":"2004","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0300","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00253-011-3758-5","article-title":"CHO cells in biotechnology for production of recombinant proteins: current state and further potential","volume":"93","author":"Kim","year":"2012","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0305","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1128\/AAC.00805-10","article-title":"Gamma interferon supplementation for melioidosis","volume":"54","author":"Koh","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0310","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.0022-202X.2004.22237.x","article-title":"Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals","volume":"122","author":"Kortylewski","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0315","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/107999099314289","article-title":"Efficient human IFN-gamma expression in the mammary gland of transgenic mice","volume":"19","author":"Lagutin","year":"1999","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0320","series-title":"Therapeutic Proteins","first-page":"31","article-title":"Secretory production of therapeutic proteins in Escherichia coli","author":"Lee","year":"2005"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0325","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.5504\/BBEQ.2012.0128","article-title":"Expression of human interferon-gamma gene in human tissue culture cells","volume":"27","author":"Leister","year":"2014","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0330","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.canlet.2011.09.031","article-title":"Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1)","volume":"314","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0335","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<202::AID-SSU3>3.0.CO;2-C","article-title":"Isolated limb perfusion in primary and recurrent melanoma: indications and results","volume":"14","author":"Lienard","year":"1998","journal-title":"Semin. Surg. Oncol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(94)90031-0","article-title":"Structural elements required for receptor recognition of human interferon-gamma","volume":"64","author":"Lundell","year":"1994","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0345","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/08923973.2010.543685","article-title":"Effect of plasmid-mediated stable interferon-gamma expression on proliferation and cell death in the SKOV-3 human ovarian cancer cell line","volume":"33","author":"Lv","year":"2011","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0350","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3923\/jbs.2008.1087.1091","article-title":"The structural characterization of recombinant human interferon gamma","volume":"8","author":"Malek Sabet","year":"2008","journal-title":"J. Biol. Sci."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0355","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/422993","article-title":"Long-term interferon-gamma therapy for patients with chronic granulomatous disease","volume":"39","author":"Marciano","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0360","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1525-1438.2006.00622.x","article-title":"Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I\/II study","volume":"16","author":"Marth","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0365","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1478-3231.2008.01918.x","article-title":"Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody","volume":"29","author":"Maylin","year":"2009","journal-title":"Liver Int."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0370","series-title":"Increasing IFN-Gamma Productivity in CHO Cells Through CDK Inhibition","author":"McClain","year":"2010"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0375","series-title":"The Interferons: Characterization and Application","author":"Meager","year":"2006"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0380","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1107\/S2059798316012237","article-title":"Crystal structure of human interferon-gamma receptor 2 reveals the structural basis for receptor specificity","volume":"72","author":"Mikulecky","year":"2016","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0385","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05069.x","article-title":"Clinical use of interferon-gamma","volume":"1182","author":"Miller","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0390","doi-asserted-by":"crossref","first-page":"51068","DOI":"10.1074\/jbc.M307470200","article-title":"Glycation and post-translational processing of human interferon-gamma expressed in Escherichia coli","volume":"278","author":"Mironova","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0395","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/jps.22473","article-title":"Prolonged circulation half-life of interferon gamma activity by gene delivery of interferon gamma-serum albumin fusion protein in mice","volume":"100","author":"Miyakawa","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0400","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/oxfordjournals.jbchem.a135643","article-title":"Purification of natural human interferon-gamma by antibody affinity chromatography: analysis of constituent protein species in the dimers","volume":"99","author":"Miyata","year":"1986","journal-title":"J. Biochem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0405","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pep.2006.07.002","article-title":"Improving purification of recombinant human interferon gamma expressed in Escherichia coli; effect of removal of impurity on the process yield","volume":"51","author":"Mohammadian-Mosaabadi","year":"2007","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0410","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/dna.1986.5.181","article-title":"Efficient constitutive production of human IFN-gamma in Chinese hamster ovary cells","volume":"5","author":"Mory","year":"1986","journal-title":"DNA"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0415","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2893.2005.00689.x","article-title":"Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection","volume":"13","author":"Muir","year":"2006","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0420","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0003-9861(03)00113-9","article-title":"Human interferon gamma: significance of the C-terminal flexible domain for its biological activity","volume":"413","author":"Nacheva","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0425","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/oxfordjournals.jbchem.a123945","article-title":"Hyperproduction of human interferon gamma by rat cells maintained in low-serum medium using the fibronectin gene promoter","volume":"112","author":"Nakajima","year":"1992","journal-title":"J. Biochem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0430","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1084\/jem.158.3.670","article-title":"Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity","volume":"158","author":"Nathan","year":"1983","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0435","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2013.04.029","article-title":"IFN-gamma selectively exerts pro-apoptotic effects on tumor-initiating label-retaining colon cancer cells","volume":"336","author":"Ni","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0440","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1089\/scd.2013.0028","article-title":"IFN-gamma stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro","volume":"22","author":"Noone","year":"2013","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0445","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/j.1460-2075.1983.tb01618.x","article-title":"Monoclonal antibodies to human interferon-gamma: production, affinity purification and radioimmunoassay","volume":"2","author":"Novick","year":"1983","journal-title":"EMBO J."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0450","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"Pai","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0455","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10238-011-0164-3","article-title":"Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis","volume":"12","author":"Panahi","year":"2012","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0460","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/BF00176659","article-title":"Production and characterization of human gamma interferon from Escherichia coli","volume":"33","author":"Perez","year":"1990","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0465","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pep.2010.03.026","article-title":"Purification and refolding of recombinant human interferon-gamma in urea-ammonium chloride solution","volume":"73","author":"Petrov","year":"2010","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.procbio.2016.02.007","article-title":"Improving the production of human interferon gamma (hIFN-\u03b3) in Pichia pastoris cell factory: an approach of cell level","author":"Prabhu","year":"2016","journal-title":"Process. Biochem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0475","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.4049\/jimmunol.0903374","article-title":"Intron-containing type I and type III IFN coexist in amphibians: refuting the concept that a retroposition event gave rise to type I IFNs","volume":"184","author":"Qi","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0480","first-page":"18","article-title":"FDA biopharmaceutical product approvals and trends in 2012","volume":"11","author":"Rader","year":"2013","journal-title":"BioProcess Int."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0485","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa030511","article-title":"A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis","volume":"350","author":"Raghu","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0490","first-page":"43","article-title":"Increased expression and secretion of recombinant hIFN\u03b3 through amino acid starvation-induced selective pressure on the adjacent HIS4 gene in Pichia pastoris","volume":"62","author":"Razaghi","year":"2015","journal-title":"Acta Fac. Pharm. Univ. Comen."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0495","article-title":"Is Pichia pastoris a realistic platform for industrial production of recombinant human interferon gamma?","author":"Razaghi","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0500","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pep.2006.08.013","article-title":"Increased yield of high purity recombinant human interferon-gamma utilizing reversed phase column chromatography","volume":"52","author":"Reddy","year":"2007","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0505","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1016\/S0021-9258(17)39797-1","article-title":"Natural human interferon-gamma: complete amino acid sequence and determination of sites of glycosylation","volume":"259","author":"Rinderknecht","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0510","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s12010-012-0068-z","article-title":"Advances and drawbacks of the adaptation to Serum-Free culture of CHO-K1 cells for monoclonal antibody production","volume":"169","author":"Rodrigues","year":"2013","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0515","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.plasmid.2010.07.003","article-title":"Replicative and integrative plasmids for production of human interferon gamma in Bacillus subtilis","volume":"64","author":"Rojas Contreras","year":"2010","journal-title":"Plasmid"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0520","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0525","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0213-005X(11)70015-5","article-title":"Diagnosis of tuberculosis infection using interferon-\u03b3-based assays","volume":"29","author":"Sant\u00edn Cerezales","year":"2011","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0530","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/jir.1993.13.267","article-title":"Effect of carbohydrates on the pharmacokinetics of human interferon-gamma","volume":"13","author":"Sareneva","year":"1993","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0535","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1042\/bj3080009","article-title":"N-glycosylation of human interferon-\u03b3: glycans at Asn-25 are critical for protease resistance","volume":"308","author":"Sareneva","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0540","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1432-1033.1996.0191r.x","article-title":"Biosynthesis and N-glycosylation of human interferon-gamma. Asn25 and Asn97 differ markedly in how efficiently they are glycosylated and in their oligosaccharide composition","volume":"242","author":"Sareneva","year":"1996","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0545","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1073\/pnas.80.15.4654","article-title":"Expression and characterization of the product of a human immune interferon cDNA gene in Chinese hamster ovary cells","volume":"80","author":"Scahill","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0550","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0555","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1462-5822.2006.00716.x","article-title":"Interferon signalling network in innate defence","volume":"8","author":"Takaoka","year":"2006","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0560","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cell.2015.03.045","article-title":"Immunotherapy: the path to win the war on cancer?","volume":"161","author":"Topalian","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0565","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1128\/JCM.02411-05","article-title":"Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis","volume":"44","author":"Tsiouris","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0570","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1089\/jir.2006.26.901","article-title":"Inducible nitric oxide synthase (iNOS) activity could be responsible for resistance or sensitivity to IFN-gamma-induced apoptosis in several human hepatoma cell lines","volume":"26","author":"Vadrot","year":"2006","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0575","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s10295-009-0632-x","article-title":"Kinetic studies of recombinant human interferon-gamma expression in continuous cultures of E. coli","volume":"36","author":"Vaiphei","year":"2009","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0580","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1432-1033.1993.tb18057.x","article-title":"Refolding and single-step purification of porcine interferon-gamma from Escherichia coli inclusion bodies. Conditions for reconstitution of dimeric IFN-gamma","volume":"215","author":"Vandenbroeck","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0585","first-page":"230","article-title":"Physiological and morphological changes of recombinant E. coli during over-expression of human interferon-g in HCDC","volume":"4","author":"Varedi","year":"2006","journal-title":"Iran. J. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0590","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/glycob\/3.2.97","article-title":"Biological roles of oligosaccharides: all of the theories are correct","volume":"3","author":"Varki","year":"1993","journal-title":"Glycobiology"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0595","first-page":"768723","article-title":"The use of interferon gamma release assays in the diagnosis of active tuberculosis","volume":"2012","author":"Vesenbeckh","year":"2012","journal-title":"Tuberc. Res. Treat."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0600","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002018-199410020-00003","article-title":"Clinical toxicity of the interferons","volume":"10","author":"Vial","year":"1994","journal-title":"Drug Saf."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0605","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ni0103-8","article-title":"Novel interferons","volume":"4","author":"Vilcek","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0610","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/sj.onc.1204199","article-title":"Control of cell cycle progression in human mesothelioma cells treated with gamma interferon","volume":"20","author":"Vivo","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0615","first-page":"2487","article-title":"IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro","volume":"9","author":"Wall","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0620","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/376230a0","article-title":"Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor","volume":"376","author":"Walter","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0625","first-page":"10","article-title":"The antiproliferative activity of combination treatment of IFN-\u03b3 and doxorubicin on H22 cells: in vitro and in vivo","volume":"9","author":"Wang","year":"2009","journal-title":"Cancer Ther."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0630","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3892\/mmr.2013.1812","article-title":"Expression, purification and characterization of human interferon-gamma in Pichia pastoris","volume":"9","author":"Wang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0635","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/protein\/9.10.905","article-title":"Engineered disulfide bonds in recombinant human interferon-gamma: the impact of the N-terminal helix A and the AB-loop on protein stability","volume":"9","author":"Waschutza","year":"1996","journal-title":"Protein Eng."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0640","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00000421-198808000-00011","article-title":"A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma","volume":"11","author":"Welander","year":"1988","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0645","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1200\/JCO.1995.13.9.2324","article-title":"Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer","volume":"13","author":"Wiesenfeld","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0650","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1054\/bjoc.1999.1053","article-title":"Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial","volume":"82","author":"Windbichler","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0655","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ar.22661","article-title":"Adenovirus-mediated interferon-gamma gene therapy induced human pancreatic carcinoma Capan-2 cell apoptosis in vitro and in vivo","volume":"296","author":"Xie","year":"2013","journal-title":"Anat. Rec. (Hoboken)"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0660","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.79.6.1820","article-title":"Purification of two subspecies of human gamma (immune) interferon","volume":"79","author":"Yip","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0665","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jps.10007","article-title":"Interferon-gamma therapy: evaluation of routes of administration and delivery systems","volume":"91","author":"Younes","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0670","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1021\/bi00391a031","article-title":"Sedimentation equilibrium measurements of recombinant DNA derived human interferon gamma","volume":"26","author":"Yphantis","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0675","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","article-title":"The two faces of interferon-gamma in cancer","volume":"17","author":"Zaidi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0680","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0021-9673(92)85539-6","article-title":"Production, purification and characterization of recombinant human interferon gamma","volume":"604","author":"Zhang","year":"1992","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0685","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.lfs.2007.05.028","article-title":"Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth","volume":"81","author":"Zhao","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0690","series-title":"Recent Advances in Glycosylation Modifications in the Context of Therapeutic Glycoproteins","author":"Zhong","year":"2012"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0695","doi-asserted-by":"crossref","first-page":"e19407","DOI":"10.1371\/journal.pone.0019407","article-title":"Minicircle-oriP-IFNgamma: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma","volume":"6","author":"Zuo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jbiotec.2016.10.022_bib0700","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/thx.2010.143180","article-title":"Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review","volume":"67","author":"Zwerling","year":"2012","journal-title":"Thorax"}],"container-title":["Journal of Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165616315784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165616315784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T15:03:00Z","timestamp":1657551780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168165616315784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":140,"alternative-id":["S0168165616315784"],"URL":"https:\/\/doi.org\/10.1016\/j.jbiotec.2016.10.022","relation":{},"ISSN":["0168-1656"],"issn-type":[{"value":"0168-1656","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation","name":"articletitle","label":"Article Title"},{"value":"Journal of Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbiotec.2016.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}